The U.S. Food and Drug Administration today approved Arexvy™, the first single-dose, respiratory syncytial virus (RSV) vaccine approved for use in the United States.
GSK plc's Arexvy is approved for preventing lower respiratory tract disease (LRTD) caused by RSV in individuals 60 and older.
The U.S. launch is planned before the start of the 2023/24 RSV season.
Initial RSV Vaccine Approved in the U.S.
Changes in Cancer Risk Factors, Screening Reported During Pandemic
Declines seen in current smoking, physical inactivity, heavy alcohol consumption; increase seen in uptake of HPV vaccine, stool testing for CRC